Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) FCF Margin (2016 - 2025)

Historic FCF Margin for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to 24576.27%.

  • BioRestorative Therapies' FCF Margin fell 238237000.0% to 24576.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 2816.04%, marking a year-over-year decrease of 7910400.0%. This contributed to the annual value of 2078.94% for FY2024, which is 24486700.0% up from last year.
  • According to the latest figures from Q3 2025, BioRestorative Therapies' FCF Margin is 24576.27%, which was down 238237000.0% from 890.21% recorded in Q2 2025.
  • Over the past 5 years, BioRestorative Therapies' FCF Margin peaked at 752.57% during Q3 2024, and registered a low of 44818.08% during Q4 2022.
  • In the last 5 years, BioRestorative Therapies' FCF Margin had a median value of 5450.99% in 2024 and averaged 9299.9%.
  • Its FCF Margin has fluctuated over the past 5 years, first skyrocketed by 362274800bps in 2023, then plummeted by -238237000bps in 2025.
  • BioRestorative Therapies' FCF Margin (Quarter) stood at 22900.28% in 2021, then plummeted by -96bps to 44818.08% in 2022, then soared by 81bps to 8590.6% in 2023, then skyrocketed by 37bps to 5450.99% in 2024, then crashed by -351bps to 24576.27% in 2025.
  • Its FCF Margin was 24576.27% in Q3 2025, compared to 890.21% in Q2 2025 and 11345.6% in Q1 2025.